EP0230402B1 - Dérivés d'alkylol pharmacologiquement actifs - Google Patents

Dérivés d'alkylol pharmacologiquement actifs Download PDF

Info

Publication number
EP0230402B1
EP0230402B1 EP87830012A EP87830012A EP0230402B1 EP 0230402 B1 EP0230402 B1 EP 0230402B1 EP 87830012 A EP87830012 A EP 87830012A EP 87830012 A EP87830012 A EP 87830012A EP 0230402 B1 EP0230402 B1 EP 0230402B1
Authority
EP
European Patent Office
Prior art keywords
piperazin
dihydroxypropyl
hydroxy
alkylol
propane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP87830012A
Other languages
German (de)
English (en)
Other versions
EP0230402A3 (en
EP0230402A2 (fr
Inventor
Roberto P. Giani
Salvatore Malandrino
Giancarlo Tonon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe Farmaceutici SpA
Original Assignee
Dompe Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farmaceutici SpA filed Critical Dompe Farmaceutici SpA
Priority to AT87830012T priority Critical patent/ATE88467T1/de
Publication of EP0230402A2 publication Critical patent/EP0230402A2/fr
Publication of EP0230402A3 publication Critical patent/EP0230402A3/en
Application granted granted Critical
Publication of EP0230402B1 publication Critical patent/EP0230402B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Definitions

  • the subject of the present invention relates to a new class of alkylol derivatives which show an interesting activity as antitussive agents.
  • the compounds of the invention are represented by alkylolpiperazine and alkylolhomopiperazine derivatives belonging to the general formula where R represents a 5 or 6 membered heterocylic ring selected among pyridine, pyrimidine, pyrazine, pyridazine, thiophene and furan which may be substituted with one or more groups selected among alkyl, trifluoromethyl, methylthio, alkoxy, halogen, amide, hydroxy, cyano, carboxy and the alkyl esters and the salts with alkali metals thereof or R represents an unsubstituted thiazolyl group n is an integer such as 2 or 3 X and X' represent each a hydrogen atom or hydroxy group with the exception of both being hydrogen atom, and X' may be also a substituted hydroxy group and the corresponding non toxic pharmaceutically acceptable acid addition salts, except the compound 3-[4-(2'-pyridyl)-piperazin-1-
  • the compounds of formula I display a marked antitussive activity and, at their active dose, practically they are free of the undesired side effects which generally are shown by the compounds on the market having analogous activity.
  • the process for preparing the compounds of formula I is essentially based on reacting a heterocyclic derivative R-Hal (II), where R has the above-cited meaning and Hal represents a halogen atom, preferably a chlorine atom, with a piperazine or homopiperazine alkylol derivative (III), in a suitable organic solvent at a temperature generally comprised between 60 and 130°C.
  • R-Hal a heterocyclic derivative
  • Hal represents a halogen atom, preferably a chlorine atom
  • a piperazine or homopiperazine alkylol derivative (III) in a suitable organic solvent at a temperature generally comprised between 60 and 130°C.
  • the reaction can be schematically represented as following where the symbols R, Hal, n, X and X' have the above mentioned meaning.
  • the compounds I are isolated according to the known technique, in good yield and purity state.
  • alkyl or alkoxy is used through the description to mean an alkyl or alkoxy radical having from 1 to 3 carbon atoms respectively.
  • substituted hydroxy means a hydroxy group substituted with an alkyl or with a hydroxyalkyl.
  • R represents an optionally substituted pyridin-2-yl radical
  • n is 2
  • X and X' are both hydroxy group.
  • the compounds I when the carboxy group is present and when desired, may be converted in a manner known per se into the corresponding alkali metal salts and they may be isolated as non-toxic addition salts with suitable acids.
  • the compounds according to the present invention are used in the form of pharmaceutical preparation which contain said compounds in admixture with pharmaceutically acceptable carriers such as an organic or inorganic solid or liquid excipient suitable for oral or parenteral administration.
  • pharmaceutically acceptable carriers such as an organic or inorganic solid or liquid excipient suitable for oral or parenteral administration.
  • the compounds of the invention may be contained in these pharmaceu tical preparation in the form of free base or in the form of their non-toxic acid addition salts.
  • the inorganic acids which may be employed to prepare these acid addition salts may be, for example, hydrochloric, hydrobromic, or sulphuric acid.
  • the organic acids which may be employed are, for example, maleic, citric, fumaric and succinic acid.
  • the pharmaceutical preparations may be in solid form as capsules, tablets, dragees or suppositories, or in liquid form such as solutions, suspensions or emulsions. If desired, there may be included in the above preparations auxiliary substances such as stabilizing agents and other commonly used additives, or there may be contained other therapeutically active agents suitable to be administered together with the componds of the invention. While the dosage of the compounds will vary from the administration route and will also depend upon the age and condition of the patient, a dosage unit from about 1 to about 20 mg per kilogram of body weight per day, can be orally administered.
  • the antitussive activity of the compounds of the invention has been evaluated using as comparison compounds both dropropizine, which represents the antitissive compound having the closest chemical structure analogy with the compounds of the invention, and codeine.
  • the compounds of the invention compared to the standard at the same dose, showed to be endowed with a higher or comparable activity and to be practically devoided of undesired side effects.
  • tests for determining the effect on the sleeping time interval induced by barbiturate administration were carried out. Tests were performed on the compounds of formula I according to the methods herebelow reported and gave the results listed in Tables 1 and 2.
  • the animals were selected the day before and allowed to the test only if they showed a number of short coughs equal or higher than 10.
  • Table 1 Compound Dose mg/Kg p.o. Inhibition % p* Codeine 100 63.17 ⁇ 0.001 Dropropizine( ⁇ ) 100 48.57 ⁇ 0.01
  • Example 1 100 42.80 ⁇ 0.01
  • Example 2 100 29.95 ⁇ 0.02
  • Example 3 100 51.66 ⁇ 0.01
  • Example 4 100 29.80 ⁇ 0.02
  • Example 5 100 64.01 ⁇ 0.001
  • Example 6 100 45.15 ⁇ 0.01
  • Example 7 100 60.00 ⁇ 0.001 * "t" of Student for paired data.
  • the sleep was induced by intraperitoneal administration of 40 mg/Kg pentobarbital sodium.
  • the narcosis start was considered from the moment when the animal, lying on its back, lost its straightening reflex.
  • the narcosis end was considered from the moment when the animal recovered such reflex. (Turner R. in "Screening Methods in Pharmacology", Academic Press, 6 ,70,1985).
  • the compounds under examination were orally administered 1 hour before the barbiturate administration; to the control animals 10 ml/Kg tap water were administered.
  • Table 2 Compound Dose mg/Kg p.o. ⁇ % p* Codeine 100 + 122.56 ⁇ 0.001 Dropropisine ( ⁇ ) 100 + 153.80 ⁇ 0.001
  • Example 1 100 + 35.12 ⁇ 0.05
  • Example 2 100 + 3.03 NS
  • Example 3 100 + 13.42
  • Example 4 100 - 3.58 NS
  • Example 5 100 - 10.23 NS
  • Example 6 100 + 1.22 NS
  • Example 7 100 - 12.80 NS * "t" of Student NS not significant

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)

Claims (11)

  1. Dérivés à groupement alkylol, ayant la formule structurale
    Figure imgb0007
     où R représente un hétérocycle penta- ou hexagonal choisi Parmi la pyridine, la pyrimidine, la pyrazine, la pyridazine, le thiophène et le furanne qui peuvent facultativement être substitués par un ou plusieurs groupes choisis parmi les groupes alkyle, trifluorométhyle, méthylthio, alcoxy, halogéno, amido, hydroxyle, cyano, carboxyle et les esters d'alkyle et sels de métaux alcalins correspondants, ou bien R représente un groupe thiazolyle non substitué, n est un nombre entier tel que 2 ou 3, X et X' représentent chacun un atome d'hydrogène ou un groupe hydroxyle, à la condition qu'ils ne représentent pas chacun un atome d'hydrogène, et X' peut également être un groupe hydroxyle substitué par un groupe alkyle ou hydroxyalkyle, et les sels d'addition d'acides non toxiques pharmaceutiquement acceptables correspondants, à l'exception du 3-[4-(2'-pyridyl)pipérazine-1-yl]-1-hydroxypropane.
  2. Dérivés à groupement alkylol selon la revendication 1, caractérisés en ce que n est 2.
  3. Dérivés à groupement alkylol selon la revendication 1, caractérisés en ce que n est 3.
  4. Dérivés à groupement alkylol selon la revendication 1, caractérisés en ce que R est un radical pyridine-2-yle facultativement substitué, n est 2, et X et X' sont chacun un groupe hydroxyle.
  5. Acide 2-[4-(2,3-dihydroxypropyl)pipérazine-1-yl]nicotinique.
  6. 3-[4-(6-chloropyridazine-3-yl)pipérazine-1-yl]-propane-1,2-diol.
  7. 2-[4-(2,3-dihydroxypropyl)pipérazine-1-yl]-nicotinamide.
  8. Acide 6-[4-(2,3-dihydroxypropyl)pipérazine-1-yl]nicotinique.
  9. Acide 2-[4-(2,3-dihydroxypropyl)homopipérazine-1-yl]nicotinique.
  10. Procédé par analogie pour la préparation de dérivés à groupement alkylol selon la revendication 1, caractérisé en ce qu'un dérivé hétérocyclique R-Hal, où R est tel que défini précédemment et Hal représente un atome d'halogène, est amené à réagir dans un solvant organique approprié à une température comprise entre 60 et 130°C avec un dérivé à groupement alkylol de formule
    Figure imgb0008
     où n, X et X' sont tels que définis précédemment, et en ce que le composé obtenu est facultativement transformé en les sels de métaux alcalins et sels d'addition d'acides pharmaceutiquement acceptables non toxiques correspondants.
  11. Composition pharmaceutique contenant une quantité active d'un ou plusieurs composés selon les revendications 1 à 9 en mélange avec un ou plusieurs diluants pharmaceutiquement acceptables.
EP87830012A 1986-01-20 1987-01-16 Dérivés d'alkylol pharmacologiquement actifs Expired - Lifetime EP0230402B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT87830012T ATE88467T1 (de) 1986-01-20 1987-01-16 Pharmakologisch aktive alkylol-derivate.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1912186 1986-01-20
IT19121/86A IT1191845B (it) 1986-01-20 1986-01-20 Alchiloli derivati farmacologicamente attivi

Publications (3)

Publication Number Publication Date
EP0230402A2 EP0230402A2 (fr) 1987-07-29
EP0230402A3 EP0230402A3 (en) 1989-02-22
EP0230402B1 true EP0230402B1 (fr) 1993-04-21

Family

ID=11154912

Family Applications (1)

Application Number Title Priority Date Filing Date
EP87830012A Expired - Lifetime EP0230402B1 (fr) 1986-01-20 1987-01-16 Dérivés d'alkylol pharmacologiquement actifs

Country Status (7)

Country Link
US (1) US4849422A (fr)
EP (1) EP0230402B1 (fr)
JP (1) JPS62169768A (fr)
AT (1) ATE88467T1 (fr)
DE (1) DE3785463T2 (fr)
ES (1) ES2056836T3 (fr)
IT (1) IT1191845B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2664238B2 (ja) * 1989-03-01 1997-10-15 日清製粉株式会社 ニコチン酸またはそのエステル誘導体
FR2675799B1 (fr) * 1991-04-24 1993-12-24 Synthelabo Derives de 2-aminopyrimidine-4-carboxamide, leur preparation et leur application en therapeutique.
WO2004083235A2 (fr) * 2003-03-19 2004-09-30 Exelixis Inc. Modulateurs de tie-2 et procedes d'utilisation
WO2005118543A1 (fr) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. Inhibiteur des kinases et utilisation de cet inhibiteur
ES2435790T3 (es) 2004-12-03 2013-12-23 Intervet International B.V. Piperazinas sustituidas como antagonistas de CB1
CA2637565A1 (fr) 2006-01-18 2007-07-26 Schering Corporation Modulateurs de recepteurs de cannibinoides
WO2009005645A1 (fr) * 2007-06-28 2009-01-08 Schering Corporation Pipérazines substituées en tant qu'antagonistes de cb1
BRPI0814806A2 (pt) 2007-06-28 2015-02-03 Intervet Int Bv Pirazinas substituídas como antagonistas de cb1
JP6047830B2 (ja) * 2013-03-12 2016-12-21 花王株式会社 ホモピペラジン誘導体を含む漂白剤組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064244A (en) * 1973-02-02 1977-12-20 Sandoz Ltd. Organic compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2257294B1 (fr) * 1973-07-06 1977-07-01 Ugine Kuhlmann
HU173380B (hu) * 1977-02-25 1979-04-28 Richter Gedeon Vegyeszet Sposob poluchenija novogo proizvodnogo piridil-piperazina i kislo-additivnykh solejj
EP0094159B1 (fr) * 1982-05-10 1990-03-14 Takeda Chemical Industries, Ltd. Dérivés de la dihydropyridine, leur préparation et leur application
DE3443698A1 (de) * 1984-11-30 1986-06-05 Sandoz-Patent-GmbH, 7850 Lörrach Neue piperazinderivate, verfahren zu ihrer herstellung und ihre verwendung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064244A (en) * 1973-02-02 1977-12-20 Sandoz Ltd. Organic compounds

Also Published As

Publication number Publication date
EP0230402A3 (en) 1989-02-22
IT1191845B (it) 1988-03-23
ATE88467T1 (de) 1993-05-15
DE3785463D1 (de) 1993-05-27
US4849422A (en) 1989-07-18
DE3785463T2 (de) 1993-11-18
EP0230402A2 (fr) 1987-07-29
ES2056836T3 (es) 1994-10-16
IT8619121A0 (it) 1986-01-20
JPS62169768A (ja) 1987-07-25

Similar Documents

Publication Publication Date Title
EP0385351B1 (fr) Dérivés de l'acide nicotinique et compositions pharmaceutiques les contenant
DE60311980T2 (de) Histondeacetylase-hemmer
EP0447857B1 (fr) Composé polycyclique, procédé pour sa préparation et compositions pharmaceutiques le contenant
US4904676A (en) Amino-oxazole compounds having dopaminergic activity
CA2107115A1 (fr) Amines heterocycliques utiles dans le traitement de l'asthme et de l'inflammation des voies respiratoires
EP0385350A1 (fr) Dérivés du pyridinecarboxamide et compositions pharmaceutiques les contenant
CA2098562A1 (fr) Derives piperazine et homopiperazine, compositions pharmaceutiques les contenant et procede pour leur preparation
US3944551A (en) N-Coumaranyl and chromanyl -methyl-or sulfur analogs thereof-N'- thiazolyl piperazines
EP0230402B1 (fr) Dérivés d'alkylol pharmacologiquement actifs
US6964960B2 (en) Indoloquinazolinones
EP0508740B1 (fr) Dérivés des thiazolidinedione, leur préparation et leur utilisation
US3868380A (en) Diphenylyl-al kanoylaminopyridines and salts thereof
EP0436734B1 (fr) Nouveaux derives d'aminopiperazine
EP0168005B1 (fr) Dérivés de semicarbazide, procédés pour leur préparation et compositions pharmaceutiques les contenant
NO172392B (no) Analogifremgangsmaate for fremstilling av 1h,3h-(1,2-c)-pyrrolo-7-tiazolkarboksamider
GB2083474A (en) N-(4-3-substituted pyridyl piperazino) alkyl azaspirodecanediones
DK151803B (da) Analogifremgangsmaade til fremstilling af n-pyrrolylpyridazinaminderivater eller farmaceutisk acceptable salte deraf
EP0314275A2 (fr) Composés de l'acide 2-pyrrolidone-5-carboxylique
US3321478A (en) Aminoethoxyphenyl amine, ether, and sulfide derivatives of pyrimidine
EP0397613A2 (fr) Aminoimidazopyridines pharmacologiquement actives
US4742062A (en) Benzylpiperazine compound and pharmaceutical composition as hypolipidemic agent
US3435036A (en) Di- and triphenylpropyl piperazine pyrimidyl and quinazolinyl compounds
US3819641A (en) 2-(2-pyridyl)-omega-phenylalkylamines
IL103229A (en) History of imidazolylmethyl-pyridine, their preparation and pharmaceutical preparations containing them
US6787546B2 (en) Heterocycle derivatives and drugs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19890718

17Q First examination report despatched

Effective date: 19910920

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19930421

Ref country code: NL

Effective date: 19930421

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19930421

Ref country code: BE

Effective date: 19930421

Ref country code: AT

Effective date: 19930421

REF Corresponds to:

Ref document number: 88467

Country of ref document: AT

Date of ref document: 19930515

Kind code of ref document: T

ITF It: translation for a ep patent filed
REF Corresponds to:

Ref document number: 3785463

Country of ref document: DE

Date of ref document: 19930527

ET Fr: translation filed
NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19940116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19940117

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19940131

Ref country code: LI

Effective date: 19940131

Ref country code: CH

Effective date: 19940131

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19940116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19940930

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19941001

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2056836

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 19990405

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050116